Details of the Drug Combinations

General Information of This Drug (ID: DMURVE8)

Drug Name

Elacridar DMURVE8

Synonyms

Elacridar hydrochloride; 143851-98-3; Elacridar HCl; Elacridar (hydrochloride); gf 120918a; UNII-NX2BHH1A5B; NX2BHH1A5B; Elacridar hydrochloride [USAN]; GF-120918A; Elacridar hydrochloride (USAN); GF 120918; AC1Q3EOG; AC1L55DX; C34H34ClN3O5; SCHEMBL15847793; CHEMBL2074730; AOB5938; MolPort-023-332-877; BCP14056; 7066AA; AKOS016005297; CS-1113; ACN-041487; 4CA-0489; HY-50880; AC-30266; FT-0696337; W-5457; D03968; N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide hydro

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

12 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
AST-487 + Elacridar	DCYPWVS	AST-487	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
Docetaxel + Elacridar	DCPRU6Y	Docetaxel	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
MLN1117 + Elacridar	DC6V48B	MLN1117	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
PF-05212384 + Elacridar	DCYHZBK	PF-05212384	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
PHA-793887 + Elacridar	DC2MHV0	PHA-793887	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
Plicamycin + Elacridar	DCUETR3	Plicamycin	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
Romidepsin + Elacridar	DCHBJJF	Romidepsin	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
Taxol + Elacridar	DC3TDIT	Taxol	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
Vinorelbine + Elacridar	DCBSEK2	Vinorelbine	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[3]
VX-680 + Elacridar	DCOAOP9	VX-680	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
VX-680 + Elacridar	DC6SISH	VX-680	Human papillomavirus-related cervical adenocarcinoma? (Cell Line: KB-3-1)	[2]
Ym155 + Elacridar	DC95U06	Ym155	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 12 DrugCom(s)

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002537)
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.